Stock Analysts’ updated eps estimates for Thursday, October 12th:

Agile Therapeutics (NASDAQ:AGRX) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $10.00 price target on the stock.

Applied Materials (NASDAQ:AMAT) had its buy rating reissued by analysts at Citigroup Inc.. Citigroup Inc. currently has a $58.00 price target on the stock.

Cerner Corporation (NASDAQ:CERN) had its overweight rating reissued by analysts at Piper Jaffray Companies. They currently have a $77.00 price target on the stock.

Wells Fargo & Company started coverage on shares of Quest Diagnostics (NYSE:DGX). Wells Fargo & Company issued a market perform rating on the stock.

HC Wainwright initiated coverage on shares of Fate Therapeutics (NASDAQ:FATE). They issued a buy rating and a $7.00 target price on the stock.

Illumina (NASDAQ:ILMN) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $230.00 target price on the stock, up from their previous target price of $215.00.

Imperial Capital initiated coverage on shares of Jagged Peak Energy (NYSE:JAG). They issued an outperform rating on the stock.

Wells Fargo & Company initiated coverage on shares of Laboratory Corporation of America Holdings (NYSE:LH). Wells Fargo & Company issued an outperform rating on the stock.

HC Wainwright initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX). HC Wainwright issued a buy rating and a $20.00 price target on the stock.

Micron Technology (NASDAQ:MU) had its overweight rating reaffirmed by analysts at Barclays PLC. They currently have a $60.00 target price on the stock, up from their previous target price of $40.00.

Sigma Designs (NASDAQ:SIGM) had its hold rating reissued by analysts at Needham & Company LLC. The analysts wrote, “Last night, SIGM announced restructuring actions for its Connected Smart TV segment that will reduce quarterly OPEX levels and accelerate the company’s return to profitability. Reflecting actions beginning in 2H of October and lasting through F4Q18, OPEX is expected to be reduced from $26MM seen in F2Q18 to $17-18MM in F1Q19, with FY19 OPEX down ~$34MM from FY18 levels. With TV staffing levels approximately cut in half, we now expect TV segment revenue to decline Y/Y in FY19 reflecting fewer resources dedicated to the business. On a positive note, the restructuring actions should pave the way for the TV business to be breakeven to modestly profitable in FY19. While the company is continuing with its review of strategic alternatives, we now see the sale of the TV business as less likely given its smaller scale.””

Standard Life Aberdeen PLC (LON:SL) had its outperform rating reissued by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a GBX 520 ($6.84) target price on the stock.

Oppenheimer Holdings, Inc. began coverage on shares of Square (NYSE:SQ). Oppenheimer Holdings, Inc. issued an outperform rating and a $35.00 target price on the stock.

Guggenheim began coverage on shares of Tactile Systems Technology (NASDAQ:TCMD). They issued a buy rating on the stock.

HC Wainwright assumed coverage on shares of TESARO (NASDAQ:TSRO). HC Wainwright issued a buy rating and a $158.00 price target on the stock.

HC Wainwright started coverage on shares of Acceleron Pharma (NASDAQ:XLRN). The firm issued a buy rating and a $57.00 price target on the stock.

Receive News & Ratings for Agile Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.